BIODESIX INC (BDSX) SEC Filings

Biodesix Inc. insider Jack W. Schuler, a more-than-10% shareholder and emeritus director, reported two open-market purchases of common stock through the Jack W. Schuler Living Trust. On August 11, 2026, the trust purchased 13,700 shares at a weighted average price of $24.0081 per share, in multiple trades between $23.965 and $24.32. On August 10, 2026, it purchased 13,900 shares at a weighted average price of $24.2467 per share, in trades between $23.89 and $24.50. The filing also reports an indirect holding of 1,800,000 shares of common stock held by the Jack W. Schuler 2026 GRAT, for which Schuler is sole trustee. Reported amounts reflect exempt transfers between the Living Trust and related GRATs under Rule 16a-13, and the transactions were not executed under a Rule 10b5-1 trading plan.

Biodesix, Inc. reported Q2 2026 revenue of $26.9 million, up from $20.0 million a year earlier, with first‑half 2026 revenue of $52.4 million versus $38.0 million. Diagnostic Tests generated $25.3 million in Q2 and $47.6 million year‑to‑date, while Development Services contributed $1.5 million and $4.8 million.

Loss from operations narrowed to $5.4 million in Q2 2026 from $9.7 million, and net loss improved to $7.3 million from $11.5 million; first‑half net loss was $15.1 million versus $22.6 million. Net loss per share was $0.71 in Q2 and $1.51 for the first half, compared with $1.56 and $3.08.

Cash, cash equivalents, and restricted cash were $30.1 million at June 30, 2026, up from $20.8 million a year earlier, after $11.7 million of operating cash use and $23.1 million of net financing inflows in the first half. The company carries a $50.0 million Perceptive Term Loan Facility, interest‑only through November 21, 2028, and reported total liabilities of $86.2 million and positive stockholders’ equity of $9.1 million.

Biodesix, Inc. reported second-quarter 2026 results with total revenue of $26.9 million, a 34% year-over-year increase. Diagnostic Testing revenue was $25.4 million, up 42%, driven by 20,900 tests, a 38% volume increase and higher average revenue per test. Development Services revenue was $1.5 million, reflecting project timing.

Gross margin reached 82%, a 200-basis-point improvement. Operating expenses excluding direct costs were $27.4 million, up 7%. Net loss narrowed to $7.3 million, a 37% improvement, and Adjusted EBITDA loss improved to $3.2 million, a 56% improvement. Cash and cash equivalents were $30.0 million. Total assets were $95.3 million and stockholders’ equity improved to $9.1 million, up from a deficit at year-end 2025, while long-term notes payable were $46.8 million. Full-year 2026 revenue guidance remains $108–114 million, with the midpoint implying about 25% growth and maintaining gross margin of roughly 80% while progressing toward Adjusted EBITDA profitability.

Biodesix Inc. director and chairman John Patience reported a routine equity compensation transaction involving restricted stock units (RSUs) that converted into common shares. On June 30, 2026, he exercised 1,361 RSUs, receiving 1,361 shares of common stock, increasing his direct common stock holdings to 25,383 shares.

Following the transaction, he also directly holds 2,721 RSUs, each representing a contingent right to one share of common stock. These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to his continued service with Biodesix. The filing also lists indirect holdings of common stock held by his spouse, the John Patience Living Trust dated July 23, 1993, and Patience Enterprises LP.

Biodesix, Inc. Schedule 13G shows Soleus Capital Master Fund, L.P. and affiliated entities report beneficial ownership of 525,241 shares of Biodesix common stock. The filing states this equals 5.1% of the class, based on 10,355,809 shares outstanding as of May 20, 2026.

The filing attributes the shares to the Master Fund and lists related entities and Guy Levy with shared voting and dispositive power over the 525,241 shares; the filing includes a standard disclaimer that affiliated entities and Mr. Levy disclaim beneficial ownership except for Section 13(d) purposes.

Biodesix, Inc. registers the resale of up to 375,000 shares of its common stock for the selling stockholder pursuant to registration rights.

The prospectus covers resale of shares issuable upon exercise of Perceptive’s warrant certificates and states the company will not receive proceeds from these resale transactions; cash proceeds would be received only if the warrants are exercised for cash.

Biodesix, Inc. is registering up to 375,000 shares of common stock for resale by Perceptive Credit Holdings IV, LP. This prospectus registers resale rights for shares issuable upon exercise of warrant certificates granted under multiple amendments to a credit agreement. The Company will not receive proceeds from resale; any cash exercise proceeds would be received by the Company. The filing discloses a Beneficial Ownership Limitation that prevents Perceptive from exercising warrants if post-exercise ownership would exceed 9.99%. The prospectus lists 10,355,809 shares outstanding as of May 20, 2026 and states the Nasdaq last sale price was $14.37 on May 20, 2026.

Biodesix, Inc. reported the results of its 2026 annual meeting of stockholders. Stockholders elected two Class III directors to serve until the 2029 annual meeting, approved on a non-binding advisory basis the compensation of named executive officers, and chose to hold say-on-pay votes every year.

They also ratified the appointment of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. A total of 10,107,219 shares of common stock were entitled to vote as of the March 23, 2026 record date.